Neurocrine Biosciences (NBIX) Cash & Equivalents (2010 - 2026)

Neurocrine Biosciences has reported Cash & Equivalents for 17 years, with the latest figure at $266.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 37.3% year-over-year to $266.5 million; the trailing twelve-month figure through Mar 2026 stood at $266.5 million (up 37.3% YoY), and the FY2025 full-year result was $713.0 million, up 206.01% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $266.5 million, down from $713.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $713.0 million in Q4 2025, with the low at $103.8 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $272.3 million across 5 years, with a median of $264.0 million in 2025.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 61.58% — and 2024, when it jumped 281.79%.
• Neurocrine Biosciences' Cash & Equivalents stood at $270.7 million in 2022, then slipped by 4.29% to $259.1 million in 2023, then decreased by 10.07% to $233.0 million in 2024, then soared by 206.01% to $713.0 million in 2025, then tumbled by 62.62% to $266.5 million in 2026.
• The last three Cash & Equivalents figures came in at $266.5 million (Q1 2026), $713.0 million (Q4 2025), and $340.2 million (Q3 2025), per Business Quant data.